HUE050896T2 - Genetikai függõség kockázatelemzése az RDS súlyossági mutatója és a készlet számára - Google Patents

Genetikai függõség kockázatelemzése az RDS súlyossági mutatója és a készlet számára

Info

Publication number
HUE050896T2
HUE050896T2 HUE15818821A HUE15818821A HUE050896T2 HU E050896 T2 HUE050896 T2 HU E050896T2 HU E15818821 A HUE15818821 A HU E15818821A HU E15818821 A HUE15818821 A HU E15818821A HU E050896 T2 HUE050896 T2 HU E050896T2
Authority
HU
Hungary
Prior art keywords
rds
kit
risk analysis
severity index
addiction risk
Prior art date
Application number
HUE15818821A
Other languages
English (en)
Inventor
Kenneth Blum
Original Assignee
Synaptamine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synaptamine Inc filed Critical Synaptamine Inc
Publication of HUE050896T2 publication Critical patent/HUE050896T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16Z—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS, NOT OTHERWISE PROVIDED FOR
    • G16Z99/00—Subject matter not provided for in other main groups of this subclass
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2537/00—Reactions characterised by the reaction format or use of a specific feature
    • C12Q2537/10—Reactions characterised by the reaction format or use of a specific feature the purpose or use of
    • C12Q2537/165—Mathematical modelling, e.g. logarithm, ratio
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/124—Animal traits, i.e. production traits, including athletic performance or the like
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/40—Population genetics; Linkage disequilibrium
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medical Informatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Pathology (AREA)
  • Databases & Information Systems (AREA)
  • Epidemiology (AREA)
  • Data Mining & Analysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Primary Health Care (AREA)
  • Evolutionary Computation (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Bioethics (AREA)
  • Software Systems (AREA)
  • Artificial Intelligence (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
HUE15818821A 2014-07-10 2015-07-10 Genetikai függõség kockázatelemzése az RDS súlyossági mutatója és a készlet számára HUE050896T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462023144P 2014-07-10 2014-07-10

Publications (1)

Publication Number Publication Date
HUE050896T2 true HUE050896T2 (hu) 2021-01-28

Family

ID=55065001

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE15818821A HUE050896T2 (hu) 2014-07-10 2015-07-10 Genetikai függõség kockázatelemzése az RDS súlyossági mutatója és a készlet számára

Country Status (8)

Country Link
US (4) US10072289B2 (hu)
EP (2) EP3751007A1 (hu)
DK (1) DK3167080T3 (hu)
ES (1) ES2813377T3 (hu)
HU (1) HUE050896T2 (hu)
PL (1) PL3167080T3 (hu)
PT (1) PT3167080T (hu)
WO (1) WO2016007927A1 (hu)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6935079B2 (ja) * 2017-05-09 2021-09-15 国立大学法人千葉大学 機能的ｓｎｐの組合せ解析
JP2022527379A (ja) 2019-03-18 2022-06-01 ジェネウス ヘルス，エルエルシー 心的外傷後ストレス障害のための遺伝子リスク分析及びその行動管理
CA3137128A1 (en) 2019-04-17 2020-10-22 Geneus Health, Llc Genetic risk analysis for attention deficit/hyperactivity disorders and behavioral management thereof
WO2020247490A1 (en) * 2019-06-04 2020-12-10 Genemarkers, Llc Risk evaluation of genomic susceptibility to opioid addiction
EP4022066A4 (en) * 2019-08-27 2023-08-30 Prescient Medicine Holdings, Inc. METHODS AND SYSTEMS FOR ASSESSING RISK OF SUBSTANCE USE DISORDERS
WO2021055856A1 (en) * 2019-09-18 2021-03-25 Millennium Health, LLC Tool for predicting health and drug abuse crisis
WO2021173869A1 (en) * 2020-02-26 2021-09-02 Ethan Russo Methods and kits for treating or diagnosing cannabinoid hyperemesis syndrome
AU2021314061A1 (en) * 2020-07-23 2023-03-16 The DNA Company Inc. Systems and methods for determining a physiological profile using genetic information
US12068066B2 (en) * 2021-03-01 2024-08-20 Kpn Innovations, Llc. System and method for generating an addiction nourishment program

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6494798A (en) 1997-02-03 1998-08-25 Max-Delbruck-Centrum Fur Molekulare Medizin Genomic sequence of the human mu-opioid receptor gene and the variants, polymorphisms and mutations thereof
US6955873B1 (en) 2000-08-04 2005-10-18 Kenneth Blum Diagnosis and treatment system for reward deficiency syndrome (RDS) and related behaviors
US8688385B2 (en) * 2003-02-20 2014-04-01 Mayo Foundation For Medical Education And Research Methods for selecting initial doses of psychotropic medications based on a CYP2D6 genotype
US20050069936A1 (en) * 2003-09-26 2005-03-31 Cornelius Diamond Diagnostic markers of depression treatment and methods of use thereof
US20060062859A1 (en) * 2004-08-05 2006-03-23 Kenneth Blum Composition and method to optimize and customize nutritional supplement formulations by measuring genetic and metabolomic contributing factors to disease diagnosis, stratification, prognosis, metabolism, and therapeutic outcomes
EP2252705A1 (en) 2008-02-22 2010-11-24 Duke University Methods and compositions for predicting success in addictive substance cessation and for predicting a risk of addiction
EP2485747A4 (en) * 2008-06-21 2013-10-23 Kenneth Blum CUSTOMIZATION DIRECTED BY THE DNA OF ANALGESIC COMPOUNDS AS A THERAPEUTIC MODALITY
EP2585824A4 (en) * 2010-04-22 2014-01-01 Kenber Llc ANALYSIS OF GENETIC RISK IN REWARDS DEFICIT SYNDROME

Also Published As

Publication number Publication date
WO2016007927A1 (en) 2016-01-14
PT3167080T (pt) 2020-09-01
EP3751007A1 (en) 2020-12-16
US20160032391A1 (en) 2016-02-04
US20160032369A1 (en) 2016-02-04
ES2813377T3 (es) 2021-03-23
US20160012180A1 (en) 2016-01-14
DK3167080T3 (da) 2020-08-31
EP3167080A4 (en) 2018-01-17
EP3167080B1 (en) 2020-05-27
US10072289B2 (en) 2018-09-11
PL3167080T3 (pl) 2020-11-16
EP3167080A1 (en) 2017-05-17
US20190112644A1 (en) 2019-04-18

Similar Documents

Publication Publication Date Title
IL252126A0 (en) Transduction methods and cellular processing
IL248299B (en) A method and kit for determining the cellular or tissue source of DNA
PL3167080T3 (pl) Analiza ryzyka uzależnienia genetycznego dla wskaźnika ciężkości rds i zestaw
SG11201606193RA (en) Biomolecule analysis kit and biomolecule analysis method
GB201708360D0 (en) Methods for determining health risks
PL3120129T3 (pl) Pojemnik na próbki rdzeniowe
EP3120313A4 (en) System and method for identifying user habits
GB2550006B (en) Establishing presence by identifying audio sample and position
GB201514411D0 (en) Kit and method
SG11201704744QA (en) Methods and kits for purifying plasmid dna
HUE048525T2 (hu) Új szelekciós marker sejt transzfekció és fehérje termelés céljára
GB201418242D0 (en) Genetic biomarkers and method for evaluating cancers
EP3111210A4 (en) Methods and reagents for riboswitch analysis
GB201417372D0 (en) Methods and kits
EP2971157A4 (en) KIT AND METHOD FOR CLASSIFYING KIR3DL1 ALLELES
GB201418980D0 (en) Cell assay kit and method
EP3199935A4 (en) Sample extraction kit and sample extraction method
ZA201803038B (en) Method and kit for identifying gene mutations
GB201415895D0 (en) DNA genetic testing kit
GB2526291B (en) Speech analysis
GB201403494D0 (en) Identifying cell features
GB201421904D0 (en) Methods and kits
GB201504515D0 (en) Fully automated knife sharpener
GB201406100D0 (en) Epigenetic rejuvenation - ips cell method
AU2014900425A0 (en) Improved methods for assessing opal bodytone and automated opal grading